News
RHHBY
30.40
+1.13%
0.34
Tech advances are catalyzing the Health Care sector with improved investor sentiment - SSGA
Healthcare Tech advances are catalyzing the Health Care sector with improved investor sentiment. The healthcare sector has seen higher earnings growth and help from advancing technologies. The sector is one of the few that has better long-term performance in Europe than in the US. European pharmaceutical and biotech companies have promising research and development productivity.
Seeking Alpha · 15h ago
Roche Announces FDA Approval For Alecensa
NASDAQ · 1d ago
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
Dow Jones · 1d ago
BRIEF-Roche Receives US Approval For Cancer Drug Alecensa
Reuters · 1d ago
FDA Approves Genentech's Alecensa For ALK-positive Early-Stage Lung Cancer
NASDAQ · 1d ago
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment
Dow Jones · 1d ago
Health Rounds: Urine tests finds worrisome prostate cancer, avoids unneeded biopsies
Health Rounds: Urine tests finds worrisome prostate cancer, avoids unneeded biopsies. A urine test detects prostate cancer in of treatment more accurately than standard blood tests. A single injection of an experimental drug for people with hard-to-control high blood pressure. The other is a urine test for detecting prostate cancer that may reduce the for biopsy.
Reuters · 1d ago
FDA approves Roche's Alecensa for early stage ALK+ lung cancer
Seeking Alpha · 1d ago
FDA APPROVES GENENTECH'S ALECENSA AS FIRST ADJUVANT TREATMENT FOR PEOPLE WITH ALK-POSITIVE EARLY-STAGE LUNG CANCER
Reuters · 1d ago
UBS Sticks to Its Hold Rating for Roche Holding AG (RHHVF)
TipRanks · 1d ago
TG Therapeutics wins VA contract for Briumvi
Seeking Alpha · 1d ago
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Seeking Alpha · 2d ago
TG Therapeutics: The Cloud Over Briumvi
Seeking Alpha · 2d ago
Roche Announces Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression Of Clinical Relapses And Brain Lesions In Patients With Progressive And Relapsing Forms Of MS
Results from the Phase III study showed near-complete suppression of relapse activity and MRI lesions. The subcutaneous injection has the potential to expand the usage of Ocrevus to treatment centers without IV infrastructure. EU approval anticipated mid-2024 and U.S. Approval anticipated September 2024.
Benzinga · 3d ago
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
Seeking Alpha · 3d ago
VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'
Seeking Alpha · 3d ago
As more rare disease therapies launch, their prices are rising
Therapies that treat rare diseases are among the most expensive treatments for patients. The most expensive medicine in the world, Lenmeldy, comes with a wholesale price of $4.25M. Cantor Fitzgerald says the prices of rare disease therapies have been increasing since 2021.
Seeking Alpha · 3d ago
Adaptimmune (ADAP) Down on End of Collaboration With Roche
NASDAQ · 4d ago
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche announced topline data from Phase 3 STARGLO study of Columvi in certain subset of patients with diffuse large B-cell lymphoma. Earlier this year, Roche terminated two cancer drug deals. The drug is the first fixed-duration antibody to receive FDA accelerated approval.
Benzinga · 4d ago
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
NASDAQ · 4d ago
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.